Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer
Bo Gao(Sun Yat-sen University), Neville F. Hacker(New South Wales Department of Health), Anthony Proietto(John Hunter Hospital), Nirmala Pandeya(University of Queensland), Karen L. Harrap(QIMR Berghofer Medical Research Institute), A Green(QIMR Berghofer Medical Research Institute), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Michelle J. Henderson(New South Wales Department of Health), Amanda Glasgow(John Hunter Hospital), Sharon E. Johnatty(QIMR Berghofer Medical Research Institute), Michael Friedländer(Prince of Wales Hospital), Dorota M. Gertig(The University of Melbourne), Anna DeFazio(The University of Sydney), David Nevell(Royal North Shore Hospital), Peter Clingan(Illawarra Health and Medical Research Institute), T. Sadkowsky(QIMR Berghofer Medical Research Institute), Georgia Chenevix‐Trench(QIMR Berghofer Medical Research Institute), C. Camaris(Royal Hospital for Women), Amanda J. Russell(University of Minnesota), Fred Kirsten(Bankstown Lidcombe Hospital), David Bell, Sián Fereday(Peter MacCallum Cancer Centre), Laura Galletta(Peter MacCallum Cancer Centre), Tony Bonaventura(St Vincent’s Private Hospital Sydney), Sue Valmadre(Royal North Shore Hospital), Stephen Begbie(Chinese University of Hong Kong), Stephen Braye(The University of Sydney), Greg Gard(Royal North Shore Hospital), James Stewart(Mater Misericordiae Hospital), Alan Ferrier(Royal North Shore Hospital), Mark Wong, Josie Rutovitz(Hornsby Ku-ring-gai Hospital), Jonathan Beesley(QIMR Berghofer Medical Research Institute), Sue Healey(QIMR Berghofer Medical Research Institute), Greg Otton(John Hunter Hospital), Catherine Emmanuel(Peter MacCallum Cancer Centre), Robin Stuart‐Harris(Bankstown Lidcombe Hospital), Roger Crouch(Royal Hospital for Women), Jennifer Shannon(The University of Sydney), Sue Moore(Ovarian Cancer Action), Nick Pavlakis(Royal North Shore Hospital), Jillian A. Hung(Millennium Institute), Nadia Traficante(The University of Melbourne), L. Edwards(Royal Hospital for Women), Sally Baron‐Hay(Royal North Shore Hospital)
Cited by 36
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k